Nanovesicle‐Mediated Targeted Delivery of Immune Checkpoint Blockades to Potentiate Therapeutic Efficacy and Prevent Side Effects

The right Timing, right combination, right sequence, and right delivery for Cancer immunotherapy

(2021) Minsu Kwon et al.   JOURNAL OF CONTROLLED RELEASE

Advances in the development of personalized neoantigen-based therapeutic cancer vaccines

(2021) Eryn Blass et al.   Nature Reviews Clinical Oncology

The role of T cell trafficking in CTLA-4 blockade-induced gut immunopathology

(2020) Shashuang Zhang et al.   BMC BIOLOGY

In Vitro Modeling of the Tumor Microenvironment in Tumor Organoids

(2020) Mahesh Devarasetty et al.   Tissue Engineering and Regenerative Medicine

Immune-related adverse events of checkpoint inhibitors

(2020) Manuel Ramos-Casals et al.   Nature Reviews Disease Primers

Nanovesicles derived from iron oxide nanoparticles–incorporated mesenchymal stem cells for cardiac repair

(2020) Ju-Ro Lee et al.   Science Advances

Molecular Pathways of Colon Inflammation Induced by Cancer Immunotherapy

(2020) Adrienne M. Luoma et al.   CELL

Antitumour dendritic cell vaccination in a priming and boosting approach

(2020) Alexandre Harari et al.   NATURE REVIEWS DRUG DISCOVERY

Studying Adipose Tissue in the Breast Tumor Microenvironment In Vitro: Progress and Opportunities

(2020) David Mertz et al.   Tissue Engineering and Regenerative Medicine

PD-L1 on dendritic cells attenuates T cell activation and regulates response to immune checkpoint blockade

(2020) Qi Peng et al.   Nature Communications

Understanding adverse events of immunotherapy: A mechanistic perspective

(2020) Kelly P. Burke et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Immune checkpoint inhibitor-induced colitis: A comprehensive review

(2019) Aniruddh Som et al.   World Journal of Clinical Cases

Maleimide–thiol adducts stabilized through stretching

(2019) Wenmao Huang et al.   Nature Chemistry

Protein inhibitor of activated STAT3 reduces peripheral arthritis and gut inflammation and regulates the Th17/Treg cell imbalance via STAT3 signaling in a mouse model of spondyloarthritis

(2019) Hong-Ki Min et al.   Journal of Translational Medicine

A Dual Immunotherapy Nanoparticle Improves T-Cell Activation and Cancer Immunotherapy

(2018) Yu Mi et al.   ADVANCED MATERIALS

Comparative evaluation of cell- and serum-derived exosomes to deliver immune stimulators to lymph nodes

(2018) Gyeonghui Yu et al.   BIOMATERIALS

Therapeutic Efficacy-Potentiated and Diseased Organ-Targeting Nanovesicles Derived from Mesenchymal Stem Cells for Spinal Cord Injury Treatment

(2018) Han Young Kim et al.   NANO LETTERS

Immune-Related Adverse Events Associated with Immune Checkpoint Blockade

(2018) Michael A. Postow et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phytochemicals as modulators of M1-M2 macrophages in inflammation

(2018) Uzma Saqib et al.   Oncotarget

Naturally derived Heme-Oxygenase 1 inducers attenuate inflammatory responses in human dendritic cells and T cells: relevance for psoriasis treatment

(2018) Nicole K. Campbell et al.   Scientific Reports

Delivery Strategies for Immune Checkpoint Blockade

(2018) Qian Chen et al.   Advanced Healthcare Materials

Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations

(2018) Judith A. Seidel et al.   Frontiers in Oncology

Towards superior dendritic-cell vaccines for cancer therapy

(2018) Mansi Saxena et al.   Nature Biomedical Engineering

Toward Biomaterials for Enhancing Immune Checkpoint Blockade Therapy

(2018) Qin Fan et al.   ADVANCED FUNCTIONAL MATERIALS

PEGylated tumor cell membrane vesicles as a new vaccine platform for cancer immunotherapy

(2018) Lukasz J. Ochyl et al.   BIOMATERIALS

RNAi-Mediated β-Catenin Inhibition Promotes T Cell Infiltration and Antitumor Activity in Combination with Immune Checkpoint Blockade

(2018) Shanthi Ganesh et al.   MOLECULAR THERAPY

A phase II trial of recombinant MAGE-A3 protein with immunostimulant AS15 in combination with high-dose Interleukin-2 (HDIL2) induction therapy in metastatic melanoma

(2018) Jennifer L. McQuade et al.   BMC CANCER

Intralymphatic Immunotherapy: Update and Unmet Needs

(2018) Gabriela Senti et al.   INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY

Toll-like receptor 4 stimulation with monophosphoryl lipid A ameliorates motor deficits and nigral neurodegeneration triggered by extraneuronal α-synucleinopathy

(2017) Serena Venezia et al.   Molecular Neurodegeneration

In situ activation of platelets with checkpoint inhibitors for post-surgical cancer immunotherapy

(2017) Chao Wang et al.   Nature Biomedical Engineering

Targeting regulatory T cells in tumors

(2016) Chang Liu et al.   FEBS Journal

Dendritic cell–derived exosomes for cancer therapy

(2016) Jonathan M. Pitt et al.   JOURNAL OF CLINICAL INVESTIGATION

Targeting PD-1 and Tim-3 Pathways to Reverse CD8 T-Cell Exhaustion and Enhance Ex Vivo T-Cell Responses to Autologous Dendritic/Tumor Vaccines

(2016) Jingwei Liu et al.   JOURNAL OF IMMUNOTHERAPY

Enhanced Cancer Immunotherapy by Microneedle Patch-Assisted Delivery of Anti-PD1 Antibody

(2016) Chao Wang et al.   NANO LETTERS

Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy

(2016) Se Jin Im et al.   NATURE

Photothermal therapy with immune-adjuvant nanoparticles together with checkpoint blockade for effective cancer immunotherapy

(2016) Qian Chen et al.   Nature Communications

A phase I trial combining decitabine/dendritic cell vaccine targeting MAGE-A1, MAGE-A3 and NY-ESO-1 for children with relapsed or therapy-refractory neuroblastoma and sarcoma

(2015) Deepa K. Krishnadas et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Landscape of Tumor Antigens in T Cell Immunotherapy

(2015) S. Ilyas et al.   JOURNAL OF IMMUNOLOGY

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

(2015) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLC

(2015) Benjamin Besse et al.   OncoImmunology

Baseline circulating IL-17 predicts toxicity while TGF-β1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma

(2015) Ahmad A. Tarhini et al.   Journal for ImmunoTherapy of Cancer

Altered T Lymphocyte Proliferation upon Lipopolysaccharide Challenge Ex Vivo

(2015) Fanny Poujol et al.   PLoS One

Long-Term Stabilization of Maleimide–Thiol Conjugates

(2014) Shaun D. Fontaine et al.   BIOCONJUGATE CHEMISTRY

Trastuzumab emtansine: mechanisms of action and drug resistance

(2014) Mark Barok et al.   BREAST CANCER RESEARCH

Cellular Metabolism and Macrophage Functional Polarization

(2014) Linnan Zhu et al.   INTERNATIONAL REVIEWS OF IMMUNOLOGY

CTLA-4 blockade and the renaissance of cancer immunotherapy

(2013) Simone Mocellin et al.   BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER

Controlled Local Delivery of CTLA-4 Blocking Antibody Induces CD8+ T-Cell-Dependent Tumor Eradication and Decreases Risk of Toxic Side Effects

(2013) M. F. Fransen et al.   CLINICAL CANCER RESEARCH

Nivolumab plus Ipilimumab in Advanced Melanoma

(2013) Jedd D. Wolchok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Reduction of Inflammatory Responses and Enhancement of Extracellular Matrix Formation by Vanillin-Incorporated Poly(Lactic-co-Glycolic Acid) Scaffolds

(2012) Yujung Lee et al.   TISSUE ENGINEERING PART A

Blockade of cytotoxic T-lymphocyte antigen-4 as a new therapeutic approach for advanced melanoma

(2011) Xiang-Yang Wang et al.   EXPERT OPINION ON PHARMACOTHERAPY

The biology of cancer testis antigens: Putative function, regulation and therapeutic potential

(2011) Elisabetta Fratta et al.   Molecular Oncology

Combination CTLA-4 Blockade and 4-1BB Activation Enhances Tumor Rejection by Increasing T-Cell Infiltration, Proliferation, and Cytokine Production

(2011) Michael A. Curran et al.   PLoS One

Tumor-Associated Macrophages Recruit CCR6+ Regulatory T Cells and Promote the Development of Colorectal Cancer via Enhancing CCL20 Production in Mice

(2011) Jinlin Liu et al.   PLoS One

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Emerging Toxicity Profiles of Anti–CTLA-4 Antibodies Across Clinical Indications

(2010) Anna Maria Di Giacomo et al.   SEMINARS IN ONCOLOGY

Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodies

(2009) Karl S. Peggs et al.   JOURNAL OF EXPERIMENTAL MEDICINE

CTLA4 blockade increases Th17 cells in patients with metastatic melanoma

(2009) Erika von Euw et al.   Journal of Translational Medicine

Dendritic Cell-Derived Exosomes Promote Natural Killer Cell Activation and Proliferation: A Role for NKG2D Ligands and IL-15Rα

(2009) Sophie Viaud et al.   PLoS One

Cytotoxic-T-Lymphocyte-Associated Antigen 4 Blockade Abrogates Protection by Regulatory T Cells in a Mouse Model of Microbially Induced Innate Immune-Driven Colitis

(2008) K. Watanabe et al.   INFECTION AND IMMUNITY